Sleep

Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.

A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

This study links NT1 to anterior hypothalamus shrinkage, advancing orexin/hypocretin insights and a potential biomarker for narcolepsy with cataplexy.

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that treatment lowers risk.

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

New smartwatch data show women's nighttime awakenings jump sharply at midlife—far more than men's—hinting at a menopause-linked sleep shift.

This eta-analysis shows sleep variability—not averages—signals psychosis risk, with stage-specific patterns to guide digital biomarkers and care.

The AI model matched or beat expert agreement on sleep arousal scoring, outperforming interscorer reliability across 10 scorers in an independent dataset.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

Longer sleep is linked to lower glycemic variability and reduced deviation risk in adolescents; higher daytime variability predicted shorter subsequent sleep.

An MRI study found hypothalamic atrophy across most subregions in adults with narcolepsy type 1, with the tuberal-inferior region relatively spared.

A new review links coexisting sleep apnea and diabetes to higher stroke risk, poorer recovery, and greater vascular damage.

LXB significantly improved nighttime sleep architecture and daytime symptoms in narcolepsy type 1 and 2, according to phase 4 DUET study results.

A 2-week sleep/light intervention shifted teens’ circadian timing earlier, increasing weeknight sleep by about 47 minutes in a randomized trial.

Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications may impact diagnostic accuracy, highlighting the need for greater standardization and clarity in clinical frameworks.

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Meta-analysis links obstructive sleep apnea to early kidney injury markers, especially in severe OSA and hypertension, highlighting need for renal monitoring.

Systematic review finds sleep disturbances in menopause are highly prevalent and linked to worse QOL, depression, pain, and reduced work productivity.

NHANES data reveal a US sleep crisis: Chronic sleep deprivation gaps tied to education, BMI, and food security, via Blinder-Oaxaca decomposition.

New IQ data show those with idiopathic hypersomnia and narcolepsy retain normal cognitive ability; fatigue, not sleepiness, hits working memory.

CBT for insomnia, especially digital CBT, often saves costs vs no treatment or drugs, while the cost-effectiveness evidence for hypersomnia remains absent.

Low-sodium oxybate (Xywav) reduces excessive sleep and daytime naps in idiopathic hypersomnia, with placebo withdrawal worsening sleep duration and symptoms.

Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.